BACKGROUND:Medical devices (MD) used to treat arrhythmias range from electrophysiological exploration catheters to intracardiac ablation catheters, and they are continuously undergoing optimization. The inclusion of innovative MD in Diagnosis Related Groups (DRG) of the French healthcare economic system can lead to financial imbalance for health institutions. The objective of this study was to compare cost-revenue analyses for interventional heart rhythm management in a high-volume French hospital between two time periods. METHODS:For 3 months in 2014 and 3 months in 2017, all of the patients admitted to the interventional rhythmic unit with arrhythmia were included retrospectively in this monocenter study. All arrhythmias were considered. The primary clinical endpoint was the difference between the expenses and incomes, calculated for each patient. The secondary endpoint was the breakdown of costs. RESULTS:217 patients were included. In 2014 period, the analysis revealed a deficit of 409±1717 euros per patient and an overall deficit for the hospital of 44,635 euros. In 2017 period, the same evaluation indicated a deficit of 446±1316 euros per patient and an overall deficit for the hospital of 48,210 euros. The cost of MD accounts for a significant share of total expenses. CONCLUSION:The profitability for the cardiac rhythm activity at our facility was optimized between 2014 and 2017. The reliance on ambulatory care increased. However, the reduction in the expenses incurred did not increase the profitability for the facility. It was offset by a decrease in DRG tariffs. A flowchart-type structure based on these practices analyses for rhythmic disorder treatments was developed.
Preserved intrinsic conduction in paced sinus node disease (SND) patients seems to be associated with a better outcome when compared with apical right ventricular (RV) DDD pacing.The prospective, multicenter, randomized OPTIMIST study was designed to compare RV lead positioning in the septum to preserved intrinsic conduction in chronically paced SND patients. SND patients with a class I indication were implanted with a DDD pacemaker (St. Jude medical), the RV lead being located in the midseptum. The algorithm VIP™ (Ventricular Intrinsic Preference) was programmed « on » in all patients at hospital discharge. After a 6 weeks observational period, patients with a ventricular pacing percentage inferior to 10% were randomized in 2 parallel groups: VIP « on » (preserved natural conduction - group 1) or « off » with AV delay optimization (RV pacing - group 2). Patients were followed every 6 months with echocardiography through 18 months. The primary endpoint was the left ventricular end-systolic diameter (LVESD) (Corelab analysis), with a non inferiority hypothesis. 216 patients mean age 76.07±9.45 were included and 167 randomized. The baseline characteristics were comparable in group 1 and 2 including left ventricular ejection fraction, LVEF (62.4±12.6 vs 64.4±8.7%), LVESD (32.7±8.5 vs 32.5±9.3mm) and 6 weeks RV pacing percentage (1.81±1.92 vs 2.15±2.07%). At the end of FU, as expected the percentage of RV pacing was significantly higher in group 2 (78.9±31.6 vs 7.9±17.4%). The LVEF was 62.3±10.1% in group 1 and 60.9±10.9% in group 2 (NS) and the LVESD was 31.9±7.23mm in group 1 and 31.26±7.21mm in group 2 (NS).The non-inferiority hypothesis was validated (p=2.572e-06 for a delta = 4.785). AF burden was not different between the 2 groups. When implanting the RV lead in the midseptum, DDD pacing with high percentage of RV capture was not associated with LV echocardiographic deterioration as compared to preserved intrinsic conduction pacing mode. January 17th, Saturday 2015